ClinicalTrials.gg
CompletedNCT06102005AIRCULESUpdated Mar 17, 2026

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

A Phase 2 interventional study of Lunsekimig and Placebo in Asthma, sponsored by Sanofi. Completed at 156 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
685
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.

Enrollment
12th of 31
685 · median 450
Started
2023
with 3 others
Phase 2
11 of 37
1 open now
Registered
33rd of 37
by date

Among the 37 studies in Asthma by Sanofi, this one is the 12th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2023, is one of 11 in phase 2, and was the 33rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Asthma by Sanofi, or all of them as a file.
02

Study summary

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A physician-diagnosed moderate-to-severe asthma for ≥12 months based on GINA guidelines Steps 4 and 5
  • Participants with existing treatment with moderate-to-high doses of ICS therapy for in combination with at least 1 but no more than 2 additional controller medications at least 3 months with a stable dose ≥1 month prior to Visit 1
  • At least 1 asthma exacerbation in the past year, with at least one exacerbation occurring while on treatment with moderate to high doses of ICS therapy
  • ACQ-5 score more than 1.5 at Screening (Visit 1)

Exclusion criteria

Exclusion Criteria:

  • Chronic obstructive or other lung diseases (eg, , idiopathic pulmonary fibrosis, etc) which may impair lung function, or another diagnosed pulmonary or systemic disease.
  • Current smoker or former smoker with cessation within 6 months of Screening or history of >10 pack-years. Active vaping of any products and/or marijuana smoking within 6 months of Screening.
  • Participants who experience a deterioration of asthma that results in emergency treatment or hospitalization, or treatment with systemic within 1 month prior to the Screening
  • Participants who have experienced an upper or lower respiratory tract infection within the 4 weeks prior to Screening
  • For participants on chronic OCS use for the maintenance treatment of asthma: history of a serious infection requiring hospitalization within the past 12 months prior to Randomization (Visit 2).
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening
  • Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
685 participants (actual)

Study arms

  • Experimental
    Lunsekimig Dose1 interval 1

    Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 1

    Drug: Lunsekimig

  • Experimental
    Lunsekimig Dose 1 interval 2

    Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 2

    Drug: Lunsekimig

  • Experimental
    Lunsekimig Dose 2 interval 1

    Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 1

    Drug: Lunsekimig

  • Experimental
    Lunsekimig Dose 2 interval 2

    Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 2

    Drug: Lunsekimig

  • Placebo comparator
    Placebo

    Participants will receive placebo (subcutaneous injection) according to established dosing intervals corresponding to Dose 1 and Dose 2

    Drug: Placebo

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • DrugPlacebo

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Annualized rate of asthma exacerbation events

    Time frame: From baseline to week 48

Secondary outcomes

  1. Change from baseline in pre-bronchodilator (BD) FEV1

    Time frame: From baseline to week 48

  2. Change from baseline in post-BD FEV1

    Time frame: From baseline to week 48

  3. The absolute change in the percent predicted FEV1 from baseline (pre-BD and post-BD)

    Time frame: From baseline to week 48

  4. Proportion of participants with ≥ 0.5-point reduction in ACQ-5 score

    ACQ-5 is Asthma control questionnaire assessing symptoms. Lower score shows better asthma control

    Time frame: From baseline to week 48

  5. Change from baseline in ACQ-5 score

    Time frame: From baseline to week 48

  6. Change from baseline in FeNO

    Time frame: From baseline to week 48

  7. Time to first asthma exacerbation

    Time frame: From baseline to week 48

  8. Annualized rate of severe asthma exacerbations requiring hospitalization or emergency room or urgent care visit

    Time frame: From baseline to week 48

  9. Average number of inhalations per day of short-acting beta 2-agoinst (SABA), Low dose ICS/formoterol or ICS/SABA for symptom relief

    Time frame: From baseline to week 48

  10. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) scores

    Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: From baseline to week 48

  11. Proportion of participants with ≥4-point improvement in SGRQ score

    Time frame: From baseline to week 48

  12. Change from baseline in Asthma Quality of Life Questionnaire Standardized for 12 years and older (AQLQ{S} +12) scores

    Time frame: From baseline to week 48

  13. Proportion of participants with ≥0.5-point improvement in AQLQ(S)+12 domain and total scores

    Time frame: From baseline to week 48

  14. Change from baseline in ACQ scores

    Time frame: From baseline to week 48

  15. Proportion of participants with ≥0.5-point reduction in ACQ-6 and ACQ-7 score

    Time frame: From baseline to week 48

  16. Serum lunsekimig concentrations

    Time frame: From baseline to week 52

  17. Anti-drug antibodies (ADA) against lunsekimig

    Time frame: From baseline to week 52

  18. Incidence of participants with treatment-emergent adverse events (TEAEs), including local reactions, adverse events of special interests (AESIs), serious adverse events (SAEs)

    Time frame: From baseline to week 52

07

Study locations

156 sites
  • Allergy, Asthma & Immunology Associates- Site Number : 8400009
    Scottsdale, Arizona 85251, United States
  • Yuma Pulmonary & Sleep Research, LLC- Site Number : 8400072
    Yuma, Arizona 85364, United States
  • Antelope Valley Clinical Trials- Site Number : 8400020
    Lancaster, California 93534, United States
  • Amicis Research Center - Northridge - Nordhoff Street- Site Number : 8400032
    Northridge, California 91324, United States
  • Optimus Medical- Site Number : 8400046
    San Francisco, California 94102, United States
  • Allergy and Asthma Associates of Santa Clara Valley Research Center- Site Number : 8400038
    San Jose, California 95117, United States
  • Clinical Trials Management Services - Thousand Oaks- Site Number : 8400053
    Thousand Oaks, California 91360, United States
  • Allianz Research Institute CO- Site Number : 8400026
    Aurora, Colorado 80014, United States
  • Velocity Clinical Research - Denver- Site Number : 8400027
    Englewood, Colorado 80110, United States
  • Western States Clinical Research- Site Number : 8400014
    Wheat Ridge, Colorado 80033, United States
  • Beautiful Minds Clinical Research Center- Site Number : 8400049
    Cutler Bay, Florida 33157, United States
  • Qway Research - Hialeah- Site Number : 8400015
    Hialeah, Florida 33010, United States
  • Clintex Research Group - Miami - Coral Way- Site Number : 8400048
    Miami, Florida 33145, United States
  • High Quality Research- Site Number : 8400039
    Miami, Florida 33184, United States
  • Innovations Biotech- Site Number : 8400040
    Miami, Florida 33186, United States
  • New Access Medical Center- Site Number : 8400043
    Miami, Florida 33186, United States
  • Deluxe Health Center- Site Number : 8400045
    Miami Lakes, Florida 33014, United States
  • Advanced Research Institute - New Port Richey- Site Number : 8400044
    New Port Richey, Florida 34653, United States
  • Pines Care Research Center- Site Number : 8400057
    Pembroke Pines, Florida 33024, United States
  • Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
    Sarasota, Florida 34239, United States
  • Appalachian Clinical Research- Site Number : 8400050
    Calhoun, Georgia 30701, United States
  • PMG Research of Christie Clinic- Site Number : 8400066
    Champaign, Illinois 61822, United States
  • Velocity Clinical Research Lafayette Site Number : 8400060
    Lafayette, Louisiana 70508, United States
  • Javara - Privia Medical Group - Annapolis- Site Number : 8400033
    Annapolis, Maryland 21401, United States
  • Brigham & Women's Hospital- Site Number : 8400034
    Boston, Massachusetts 02115, United States
  • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    Ann Arbor, Michigan 48109, United States
  • Javara - Mankato Clinic- Site Number : 8400051
    Mankato, Minnesota 56001, United States
  • Midwest Clinical Research Center - St. Louis- Site Number : 8400006
    St Louis, Missouri 63141, United States
  • Circuit Clinical - Middletown Medical - 111 Maltese Drive- Site Number : 8400065
    Middletown, New York 10940, United States
  • Icahn School of Medicine at Mount Sinai- Site Number : 8400058
    New York, New York 10029, United States
  • Carolina Clinical Research - Charlotte- Site Number : 8400071
    Charlotte, North Carolina 28273, United States
  • Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
    Charlotte, North Carolina 28287, United States
  • Clinical Research Of Gastonia- Site Number : 8400013
    Gastonia, North Carolina 28054, United States
  • Bernstein Clinical Research Center- Site Number : 8400016
    Cincinnati, Ohio 45231, United States
  • Asthma & Allergy Center - Toledo- Site Number : 8400017
    Toledo, Ohio 43617, United States
  • OK Clinical Research- Site Number : 8400021
    Edmond, Oklahoma 73034, United States
  • Velocity Clinical Research - Medford- Site Number : 8400059
    Medford, Oregon 97504, United States
  • Clinical Research Associates of Central PA - Dubois- Site Number : 8400069
    DuBois, Pennsylvania 15801, United States
  • Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
    Pittsburgh, Pennsylvania 15241, United States
  • Circuit Clinical - PMSI Comprehensive Healthcare for Life - Pottstown - Medical Drive- Site Number : 8400064
    Pottstown, Pennsylvania 19464, United States
  • VitaLink Research - Anderson - East Greenville- Site Number : 8400063
    Anderson, South Carolina 29621, United States
  • Velocity Clinical Research - Charleston- Site Number : 8400061
    Charleston, South Carolina 29414, United States
  • Orion Clinical Research- Site Number : 8400001
    Austin, Texas 78759, United States
  • South Texas Medical Research Institute - TTS Research- Site Number : 8400010
    Boerne, Texas 78006, United States
  • Baylor University Medical Center- Site Number : 8400002
    Dallas, Texas 75246, United States
  • Western Sky Medical Research- Site Number : 8400023
    El Paso, Texas 79903, United States
  • Metroplex Pulmonary and Sleep Center- Site Number : 8400022
    McKinney, Texas 75069, United States
  • VAST Clinical Research- Site Number : 8400062
    Plano, Texas 75093, United States
  • Investigational Site Number : 0320007
    Berazategui, Buenos Aires 1886, Argentina
  • Investigational Site Number : 0320003
    La Plata, Buenos Aires 1900, Argentina
  • Investigational Site Number : 0320002
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320006
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320009
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0320008
    San Miguel de Tucumán, 4000, Argentina
  • Investigational Site Number : 0320010
    Santa Fe, 3000, Argentina
  • Associacao Proar- Site Number : 0760003
    Salvador, Estado de Bahia 40060-330, Brazil
  • Universidade Federal de Goias- Site Number : 0760007
    Goiânia, Goiás 74605-020, Brazil
  • Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
    Curitiba, Paraná 80030-110, Brazil
  • Inst de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
    Recife, Pernambuco 50070-550, Brazil
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital Dia do Pulmão- Site Number : 0760005
    Blumenau, Santa Catarina 89030-101, Brazil
  • CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
    Rio de Janeiro, 22241-180, Brazil
  • Incor - Instituto do Coracao- Site Number : 0760011
    São Paulo, 05403-900, Brazil
  • Investigational Site Number : 1240003
    Hamilton, Ontario L8N 4A6, Canada
  • Investigational Site Number : 1240005
    Stoney Creek, Ontario L8G 2V6, Canada
  • Investigational Site Number : 1240004
    Sherbrooke, Quebec J1H 5N4, Canada
  • Investigational Site Number : 1240001
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Investigational Site Number : 1520010
    Valdivia, Los Ríos Region 5110683, Chile
  • Investigational Site Number : 1520001
    Talca, Maule Region 3465584, Chile
  • Investigational Site Number : 1520006
    Santiago, Reg Metropolitana de Santiago 7500587, Chile
  • Investigational Site Number : 1520005
    Santiago, Reg Metropolitana de Santiago 7500692, Chile
  • Investigational Site Number : 1520004
    Santiago, Reg Metropolitana de Santiago 7500698, Chile
  • Investigational Site Number : 1520009
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7750495, Chile
  • Investigational Site Number : 1520008
    Quillota, Valparaiso 2260877, Chile
  • Investigational Site Number : 1520011
    Viña del Mar, Valparaiso 2520598, Chile
  • Investigational Site Number : 1560011
    Beijing, 100144, China
  • Investigational Site Number : 1560010
    Changchun, 130021, China
  • Investigational Site Number : 1560017
    Changsha, 410015, China
  • Investigational Site Number : 1560008
    Chengdu, 610041, China
  • Investigational Site Number : 1560001
    Guangzhou, 510120, China
  • Investigational Site Number : 1560009
    Guangzhou, 510150, China
  • Investigational Site Number : 1560006
    Hefei, 230032, China
  • Investigational Site Number : 1560014
    Hohhot, 010050, China
  • Investigational Site Number : 1560018
    Mianyang, 621000, China
  • Investigational Site Number : 1560007
    Nanchang, 330006, China
  • Investigational Site Number : 1560002
    Pingxiang, 337055, China
  • Investigational Site Number : 1560013
    Shanghai, 200433, China
  • Investigational Site Number : 1560015
    Shenyang, 110004, China
  • Investigational Site Number : 1560005
    Wenzhou, 325027, China
  • Investigational Site Number : 1560003
    Wuhan, 430030, China
  • Investigational Site Number : 1560004
    Xuzhou, 221006, China
  • Investigational Site Number : 1560016
    Yangzhou, 225000, China
  • Investigational Site Number : 1560012
    Zhanjiang, 524004, China
  • Investigational Site Number : 3560002
    Coimbatore, 641028, India
  • Investigational Site Number : 3560006
    Delhi, 110 029, India
  • Investigational Site Number : 3560009
    Hyderabad, 500084, India

Showing the first 100 of 156 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025 Jan;134(1):9-18. doi: 10.1016/j.anai.2024.09.016. Epub 2024 Oct 10. PubMed 39393433 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Feb 2026, 28 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 28 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 26, 2023
StartActual
Oct 16, 2023
Primary completionActual
Feb 23, 2026
CompletionActual
Mar 11, 2026
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06102005
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 26, 2023
Start date
Oct 16, 2023
Primary completion
Feb 23, 2026
Completion
Mar 11, 2026
Last update
Mar 17, 2026

Study contacts

Clinial Science & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion